Home2018-07-27T04:33:28+00:00

Novel cancer therapies targeting key cancer pathways

READ MORE
Prescient Therapeutics PTX

We are a clinical stage oncology company developing novel drugs
that show great promise as potential new therapies to treat a range of cancers.

prescient therapeutics

OUR COMPANY

Prescient Therapeutics’ novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.

Digital Brochure

Two Page Fact Sheet

prescient therapeutics

OUR SCIENCE

Our technologies emanate from renowned institutions Yale University and the Moffitt Cancer Center and are backed by a myriad of peer review publications.

prescient therapeutics

LATEST NEWS

21/05/2019Investor Presentation - May 2019PDF
21/05/2019Prescient to present at Sydney ConferencePDF
16/05/2019Canadian Patent Granted for PTX-200PDF
06/05/2019Change of Director's Interest Notices x4PDF
03/05/2019Completion of Capital Raising, S708A Notice and Appendix 3BPDF
30/04/2019Completion of Entitlement Offer Allotment & Appendix 3BPDF
26/04/2019Results of MeetingPDF